Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	NOXOPHARM LIMITED	
ABN	50 608 966 123	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Fred Bart
Date of last notice	18 September 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Direct	
Nature of indirect interest (including registered holder)	N/A	
Date of change	(1) 15 September 2023	
No. of securities held prior to change	(1) 7,506,933 - ORDINARY FULLY PAID SHARES	
Class	(1) ORDINARY FULLY PAID SHARES	
Number acquired	(1) 880 - ORDINARY FULLY PAID SHARES	
Number disposed	(1) NIL	
Value/Consideration	(1) \$0.035 PER ORDINARY FULLY PAID SHARES (\$30.80 IN TOTAL)	
No. of securities held after change	(1) 7,507,813 - ORDINARY FULLY PAID SHARES	
Nature of change	(1) ON-MARKET ACQUISITION	

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A

01/01/2011 Appendix 3Y Page 1

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A